GLPG 2384
Alternative Names: GLPG2384Latest Information Update: 28 Aug 2021
Price :
$50 *
At a glance
- Originator Galapagos NV
- Class
- Mechanism of Action GPR84 protein antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for preclinical development in Unspecified in Belgium
- 26 Jul 2017 Preclinical trials in Undefined indication in Belgium (unspecified route) (Galapagos pipeline, July 2017)